ARTICLE | Company News

Interneuron deal

February 28, 1994 8:00 AM UTC

IPIC (Lexington, Mass.) received exclusive worldwide rights to Rhone-Poulenc Rorer's anti-anxiety compound, RP 62955. The drug is a partial GABA agonist. IPIC received manufacturing and marketing rights to the compound, renamed IP 456, in exchange for licensing, milestone and royalty payments. Rhone-Poulenc retained an option to market the product in France. ...